vs
Apellis Pharmaceuticals, Inc.（APLS）与SHOE CARNIVAL INC（SCVL）财务数据对比。点击上方公司名可切换其他公司
SHOE CARNIVAL INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$297.2M vs $199.9M），SHOE CARNIVAL INC净利率更高（4.9% vs -29.5%，领先34.4%），SHOE CARNIVAL INC同比增速更快（-3.2% vs -5.9%），SHOE CARNIVAL INC自由现金流更多（$19.7M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.0%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Shoe Carnival Inc是一家美国家庭鞋类零售商，目前在美国中西部、南部、东南部地区以及波多黎各共开设了429家门店。该公司由大卫·拉塞尔于1978年创立，截至2025年，其总部位于南卡罗来纳州福特米尔。
APLS vs SCVL — 直观对比
营收规模更大
SCVL
是对方的1.5倍
$199.9M
营收增速更快
SCVL
高出2.8%
-5.9%
净利率更高
SCVL
高出34.4%
-29.5%
自由现金流更多
SCVL
多$34.0M
$-14.3M
两年增速更快
APLS
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $297.2M |
| 净利润 | $-59.0M | $14.6M |
| 毛利率 | — | 37.6% |
| 营业利润率 | -25.6% | 6.3% |
| 净利率 | -29.5% | 4.9% |
| 营收同比 | -5.9% | -3.2% |
| 净利润同比 | -62.2% | -23.9% |
| 每股收益（稀释后） | $-0.40 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSCVL
| Q4 25 | $199.9M | $297.2M | ||
| Q3 25 | $458.6M | $306.4M | ||
| Q2 25 | $178.5M | $277.7M | ||
| Q1 25 | $166.8M | $262.9M | ||
| Q4 24 | $212.5M | $306.9M | ||
| Q3 24 | $196.8M | $332.7M | ||
| Q2 24 | $199.7M | $300.4M | ||
| Q1 24 | $172.3M | $280.2M |
净利润APLSSCVL
| Q4 25 | $-59.0M | $14.6M | ||
| Q3 25 | $215.7M | $19.2M | ||
| Q2 25 | $-42.2M | $9.3M | ||
| Q1 25 | $-92.2M | $14.7M | ||
| Q4 24 | $-36.4M | $19.2M | ||
| Q3 24 | $-57.4M | $22.6M | ||
| Q2 24 | $-37.7M | $17.3M | ||
| Q1 24 | $-66.4M | $15.5M |
毛利率APLSSCVL
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | — | 34.5% | ||
| Q1 25 | — | 34.9% | ||
| Q4 24 | — | 36.0% | ||
| Q3 24 | — | 36.1% | ||
| Q2 24 | — | 35.6% | ||
| Q1 24 | — | 35.6% |
营业利润率APLSSCVL
| Q4 25 | -25.6% | 6.3% | ||
| Q3 25 | 48.7% | 8.2% | ||
| Q2 25 | -18.6% | 4.3% | ||
| Q1 25 | -50.0% | 5.3% | ||
| Q4 24 | -12.3% | 8.0% | ||
| Q3 24 | -24.0% | 9.0% | ||
| Q2 24 | -14.7% | 7.5% | ||
| Q1 24 | -36.0% | 7.1% |
净利率APLSSCVL
| Q4 25 | -29.5% | 4.9% | ||
| Q3 25 | 47.0% | 6.3% | ||
| Q2 25 | -23.6% | 3.4% | ||
| Q1 25 | -55.3% | 5.6% | ||
| Q4 24 | -17.1% | 6.3% | ||
| Q3 24 | -29.2% | 6.8% | ||
| Q2 24 | -18.9% | 5.8% | ||
| Q1 24 | -38.5% | 5.5% |
每股收益（稀释后）APLSSCVL
| Q4 25 | $-0.40 | $0.53 | ||
| Q3 25 | $1.67 | $0.70 | ||
| Q2 25 | $-0.33 | $0.34 | ||
| Q1 25 | $-0.74 | $0.53 | ||
| Q4 24 | $-0.30 | $0.70 | ||
| Q3 24 | $-0.46 | $0.82 | ||
| Q2 24 | $-0.30 | $0.63 | ||
| Q1 24 | $-0.54 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $107.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $683.2M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSCVL
| Q4 25 | $466.2M | $107.7M | ||
| Q3 25 | $479.2M | $91.9M | ||
| Q2 25 | $370.0M | $93.0M | ||
| Q1 25 | $358.4M | $123.1M | ||
| Q4 24 | $411.3M | $91.1M | ||
| Q3 24 | $396.9M | $84.5M | ||
| Q2 24 | $360.1M | $69.5M | ||
| Q1 24 | $325.9M | $111.2M |
总债务APLSSCVL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSSCVL
| Q4 25 | $370.1M | $683.2M | ||
| Q3 25 | $401.2M | $670.7M | ||
| Q2 25 | $156.3M | $653.6M | ||
| Q1 25 | $164.2M | $649.0M | ||
| Q4 24 | $228.5M | $635.7M | ||
| Q3 24 | $237.1M | $618.5M | ||
| Q2 24 | $264.3M | $597.8M | ||
| Q1 24 | $266.7M | $583.4M |
总资产APLSSCVL
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $821.4M | $1.1B | ||
| Q1 25 | $807.3M | $1.1B | ||
| Q4 24 | $885.1M | $1.1B | ||
| Q3 24 | $901.9M | $1.1B | ||
| Q2 24 | $904.5M | $1.1B | ||
| Q1 24 | $831.9M | $1.0B |
负债/权益比APLSSCVL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $33.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $19.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 6.6% |
| 资本支出强度资本支出/营收 | 0.1% | 4.7% |
| 现金转化率经营现金流/净利润 | — | 2.30× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $35.1M |
8季度趋势，按日历期对齐
经营现金流APLSSCVL
| Q4 25 | $-14.2M | $33.6M | ||
| Q3 25 | $108.5M | $13.3M | ||
| Q2 25 | $4.4M | $-9.6M | ||
| Q1 25 | $-53.4M | $44.5M | ||
| Q4 24 | $19.4M | $17.3M | ||
| Q3 24 | $34.1M | $23.7M | ||
| Q2 24 | $-8.3M | $17.1M | ||
| Q1 24 | $-133.0M | $53.4M |
自由现金流APLSSCVL
| Q4 25 | $-14.3M | $19.7M | ||
| Q3 25 | $108.3M | $2.2M | ||
| Q2 25 | $4.4M | $-23.0M | ||
| Q1 25 | $-53.4M | $36.2M | ||
| Q4 24 | $19.3M | $8.3M | ||
| Q3 24 | — | $18.2M | ||
| Q2 24 | $-8.4M | $6.9M | ||
| Q1 24 | $-133.3M | $40.7M |
自由现金流率APLSSCVL
| Q4 25 | -7.1% | 6.6% | ||
| Q3 25 | 23.6% | 0.7% | ||
| Q2 25 | 2.5% | -8.3% | ||
| Q1 25 | -32.0% | 13.8% | ||
| Q4 24 | 9.1% | 2.7% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | -4.2% | 2.3% | ||
| Q1 24 | -77.3% | 14.5% |
资本支出强度APLSSCVL
| Q4 25 | 0.1% | 4.7% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.8% | ||
| Q1 25 | 0.0% | 3.2% | ||
| Q4 24 | 0.0% | 3.0% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 3.4% | ||
| Q1 24 | 0.2% | 4.5% |
现金转化率APLSSCVL
| Q4 25 | — | 2.30× | ||
| Q3 25 | 0.50× | 0.69× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | — | 3.04× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 1.05× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | — | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SCVL
暂无分部数据
